Document is current
Any future updates will be listed below
-
Authors
Wojciechowski, Piotr
Wdowiak, Marlena
Panek, Malgorzata
Lunk, Izabella
Carrasco, Joao
Zhang, Xin
Wu, Olivia
Korobelnik, Jean-François
Lanzetta, Paolo
-
Funding
Funding for this research was provided by:
Bayer AG
- License Information
-
More Information
Article History
Received: 28 November 2024
Accepted: 24 January 2025
First Online: 24 February 2025
Declarations
:
: Paolo Lanzetta consults for Aerie, Allergan, Apellis, Bausch & Lomb, Bayer, Biogen, Boehringer Ingelheim, I-Care, Genentech, Novartis, Ocular Therapeutix, Outlook Therapeutics, and Roche. Jean-Francois Korobelnik consults for Abbvie, Apellis, Bayer, Eyepoint Pharma, Janssen, NanoRetina, Roche, Thea, Carl Zeiss Meditec. Jean-Francois Korobelnik is a member of DSMB for Alexion, Novonordisk, Opthea and Oxular. Olivia Wu has received consultancy fees from Bayer for contribution to this research. Izabella Lunk, Joao Carrasco and Xin Zhang are employees of Bayer. Piotr Wojciechowski, Marlena Wdowiak and Malgorzata Panek declare that they were employed by Putnam at the time the research was conducted, a company which received funds from Bayer to conduct this research.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
